![share_log](https://pubimg.futunn.com/2021080503097442cd9f222622c.jpg?imageMogr2/thumbnail/76x76!/ignore-error/1/format/webp)
Cybin | 40-F: FY2024 Annual Report
Cybin | 40-F: FY2024 Annual Report
Cybin | 40-F:2024財年年報
牛牛AI助理已提取核心訊息
Cybin Inc. has concluded its fiscal year with several key business developments and a detailed annual report. Despite not generating revenue, the company faced a net loss of $78,080,000, with a basic loss per share of $0.25. Notable achievements include the acquisition of Small Pharma Inc., which expanded Cybin's intellectual property with 17 active patent families. The company also established a new equity program and entered into a purchase agreement with Lincoln Park Capital Fund, LLC, potentially raising up to US$65,000,000 through common share sales. Additionally, Cybin conducted multiple capital-raising efforts, including public offerings and a private placement. The company has engaged in licensing agreements, notably with Mindset Pharma Inc., to bolster its research and development. Cybin's strategy focuses on advancing psychedelic-inspired therapeutics and expanding its intellectual property through acquisitions and licensing. The company complies with regulatory frameworks across several jurisdictions and has received approvals for clinical trials. Despite the competitive market and inherent risks of the psychedelic pharmaceutical industry, Cybin continues to progress towards its business objectives.
Cybin Inc. has concluded its fiscal year with several key business developments and a detailed annual report. Despite not generating revenue, the company faced a net loss of $78,080,000, with a basic loss per share of $0.25. Notable achievements include the acquisition of Small Pharma Inc., which expanded Cybin's intellectual property with 17 active patent families. The company also established a new equity program and entered into a purchase agreement with Lincoln Park Capital Fund, LLC, potentially raising up to US$65,000,000 through common share sales. Additionally, Cybin conducted multiple capital-raising efforts, including public offerings and a private placement. The company has engaged in licensing agreements, notably with Mindset Pharma Inc., to bolster its research and development. Cybin's strategy focuses on advancing psychedelic-inspired therapeutics and expanding its intellectual property through acquisitions and licensing. The company complies with regulatory frameworks across several jurisdictions and has received approvals for clinical trials. Despite the competitive market and inherent risks of the psychedelic pharmaceutical industry, Cybin continues to progress towards its business objectives.
Cybin公司與幾項重要的業務發展和詳細的年報結束了財政年度。儘管沒有產生營業收入,公司面臨7808萬美元的淨虧損,基本每股虧損0.25美元。值得注意的成就包括收購Small Pharma公司,該公司通過17個活躍的專利族擴展了Cybin的知識產權。該公司還建立了一個新的股權計劃,並與Lincoln Park Capital Fund,LLC達成了購買協議,可能通過普通股銷售籌集高達6500萬美元。此外,Cybin進行了多次資本籌集活動,包括公開發行和定向增發。該公司參與了許可協議,尤其是與Mindset Pharma公司,以加強其研發。Cybin的策略專注於推進受迷幻劑啓發的治療法,並通過收購和許可擴展其知識產權。該公司遵守幾個司法管轄區的監管框架,並已獲得臨床試驗的批准。儘管迷幻劑藥品行業競爭激烈且存在固有風險,但Cybin仍在朝着其業務目標不斷前進。
Cybin公司與幾項重要的業務發展和詳細的年報結束了財政年度。儘管沒有產生營業收入,公司面臨7808萬美元的淨虧損,基本每股虧損0.25美元。值得注意的成就包括收購Small Pharma公司,該公司通過17個活躍的專利族擴展了Cybin的知識產權。該公司還建立了一個新的股權計劃,並與Lincoln Park Capital Fund,LLC達成了購買協議,可能通過普通股銷售籌集高達6500萬美元。此外,Cybin進行了多次資本籌集活動,包括公開發行和定向增發。該公司參與了許可協議,尤其是與Mindset Pharma公司,以加強其研發。Cybin的策略專注於推進受迷幻劑啓發的治療法,並通過收購和許可擴展其知識產權。該公司遵守幾個司法管轄區的監管框架,並已獲得臨床試驗的批准。儘管迷幻劑藥品行業競爭激烈且存在固有風險,但Cybin仍在朝着其業務目標不斷前進。
有用
沒用
譯文內容由第三人軟體翻譯。
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了